Key result
Detectable hs-cTnI was associated with higher baseline cardiovascular risk scores (P<0.0001), but 12-month changes in hs-cTnI were not consistently associated with changes in risk scores.
Why the study?
It remained unclear whether changes in hs-cTnI within the normal range are associated with variations in cardiovascular risk scores in the general population.
Do changes in hs-cTnI associate with variations in cardiovascular risk scores in a primary prevention population?
Observational (n=810)
Do changes in hs-cTnI associate with variations in cardiovascular risk scores in a primary prevention population?
While detectable hs-cTnI is associated with a worse baseline cardiovascular risk profile in primary prevention, longitudinal changes in hs-cTnI do not consistently correlate with changes in risk scores.
More patients had undetectable hs-cTnI at 12 months; hypothesis-generating for dynamic risk assessment but should not change practice.
Background In the general population, elevated hs‐cTnI (high‐sensitivity cardiac troponin I) levels are linked to adverse cardiovascular outcomes. Whether changes in hs‐cTnI within the normal range are associated with variations in cardiovascular risk scores remains unclear. Methods This observational substudy of the CV‐PREVITAL (Strategies for Primary Cardiovascular Prevention in the Italian Population) project evaluated 810 subjects (522 women) in primary prevention. Hs‐cTnI was measured at baseline and after 12 months in 473 participants. Cardiovascular risk was assessed using validated scores along with diet adherence and sleep quality. Clinical and laboratory parameters were recorded. Participants received structured lifestyle counseling. Results At baseline, hs‐cTnI was undetectable in 59% of participants. Detectable hs‐cTnI was associated with older age (58 versus 55 years), higher body mass index (26 versus 24 kg/m 2 ), greater waist circumference (91 versus 85 cm), higher blood pressure (129 versus 123 mm Hg), lower high‐density lipoprotein cholesterol (56 versus 59 mg/dL), higher glycated hemoglobin (40 versus 38 mmol/mol), all P <0.01. Progetto Cuore, Framingham Risk Score, Atherosclerotic Cardiovascular Disease, and Finnish Diabetes Risk scores were higher (all P <0.0001) in participants with detectable hs‐cTnI, whereas the Moli‐sani risk score did not differ. At 12 months, participants with undetectable hs‐cTnI increased to 79% ( P <0.0001). Although all scores but 1 improved at follow‐up, changes in hs‐cTnI were not consistently associated with changes in risk scores or therapy modifications in exploratory analyses. Conclusions In this primary‐prevention cohort, the presence of detectable hs‐cTnI was associated with a less favorable risk profile. However, its usefulness in the longitudinal monitoring of cardiovascular risk changes requires validation against cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Bachetti et al. (2026) conducted an observational in Primary cardiovascular prevention (n=810). Detectable hs-cTnI vs. Undetectable hs-cTnI was evaluated on Changes in cardiovascular risk scores. Detectable hs-cTnI was associated with higher baseline cardiovascular risk scores (P<0.0001), but 12-month changes in hs-cTnI were not consistently associated with changes in risk scores.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: